Melanotan 2

Overview

The peptide's development traces back to pioneering work at the University of Arizona in the 1980s by Drs. Victor Hruby and Mac Hadley. By substituting norleucine at position 4 and D-phenylalanine at position 7 of the native α-MSH sequence, they created a "superpotent" analog with dramatically enhanced metabolic stability and receptor binding affinity. These modifications prevent enzymatic degradation that rapidly inactivates natural α-MSH, extending the peptide's biological activity from minutes to hours.

What distinguishes Melanotan I from its more widely known counterpart Melanotan II is receptor selectivity. While Melanotan II activates multiple melanocortin receptor subtypes—producing tanning alongside effects on appetite, sexual function, and blood pressure—Melanotan I exhibits preferential affinity for the melanocortin 1 receptor (MC1R). This selectivity means its primary pharmacological effect is stimulating melanogenesis: the production of melanin pigment in skin melanocytes. The result is a measurable, UV-independent increase in skin pigmentation that provides genuine photoprotection.

Following over two decades of clinical development by the Australian company Clinuvel Pharmaceuticals, afamelanotide received EMA approval in 2014 and FDA approval in October 2019 for EPP. The approved formulation is a dissolvable subcutaneous implant that releases the peptide over approximately 60 days, eliminating the need for daily injections. Beyond EPP, active research programs are exploring afamelanotide for vitiligo, polymorphous light eruption, solar urticaria, and photoprotection in organ transplant recipients at heightened risk of skin malignancies.

ℹ️ Info: Melanotan I and Melanotan II are distinct compounds despite similar names. Melanotan I (afamelanotide) is a linear, MC1R-selective peptide with FDA approval. Melanotan II is a cyclic, non-selective melanocortin agonist with no regulatory approval. Their safety profiles, side effect spectra, and clinical evidence bases are fundamentally different.

Melanotan I's mechanism of action centers on potent, selective activation of the melanocortin 1 receptor (MC1R), a G-protein coupled receptor expressed primarily on epidermal melanocytes. When afamelanotide binds MC1R, it triggers a well-characterized intracellular signaling cascade:

Research benefits

FDA-approved photoprotection for erythropoietic protoporphyria (EPP)

Stimulates natural eumelanin production for UV-independent tanning

High MC1R selectivity with minimal off-target melanocortin effects

Demonstrated efficacy in reducing phototoxic reactions in clinical trials

Potential repigmentation therapy for vitiligo when combined with NB-UVB

Extended duration of action via subcutaneous implant delivery

Investigational photoprotection for organ transplant recipients

May reduce DNA damage from UV exposure through enhanced melanin shielding

Research applications

Erythropoietic protoporphyria (EPP) phototoxicity prevention

Active research area with published studies

Vitiligo repigmentation therapy

Active research area with published studies

Polymorphous light eruption (PMLE) prevention

Active research area with published studies

Solar urticaria management

Active research area with published studies

Photoprotection in immunosuppressed patients

Active research area with published studies

Skin cancer prevention in high-risk populations

Active research area with published studies

UV-induced DNA damage reduction

Active research area with published studies

Melanocortin receptor pharmacology

Active research area with published studies

Research findings

Afamelanotide has the most extensive clinical trial program of any melanocortin peptide, with data from multiple Phase II and Phase III studies across several dermatological conditions. Here is what the evidence demonstrates:

Erythropoietic Protoporphyria (EPP) — FDA-Approved Indication

EPP is caused by deficient ferrochelatase enzyme activity, leading to accumulation of protoporphyrin IX in red blood cells and skin. Upon light exposure, protoporphyrin IX generates reactive oxygen species causing excruciating pain, burning, and tissue damage. Patients with EPP often cannot tolerate even brief sunlight exposure.

The pivotal Phase III trial (CUV039), published in the _New England Journal of Medicine_ in 2017, randomized 94 EPP patients across the US to afamelanotide 16 mg implant or placebo every two months. The primary endpoint was duration of direct sunlight exposure between 10:00 and 18:00 without pain. Afamelanotide-treated patients spent significantly more time in sunlight—a median of 69.4 hours versus 40.8 hours for placebo over the six-month study period (p=0.04). Quality-of-life assessments showed meaningful improvements in daily activities and time spent outdoors.

A parallel European Phase III trial (CUV029) in 74 EPP patients demonstrated a 70% reduction in phototoxic reaction severity scores in the afamelanotide group versus placebo. The number of phototoxic episodes was also significantly reduced, with patients reporting approximately half the number of severe reactions compared to placebo. Both trials confirmed a favorable safety profile with nausea and implant site reactions as the most common adverse events.

✓ Good to Know: Afamelanotide is the only pharmacological therapy available for EPP. Prior to its approval, the only management option was strict light avoidance, which severely restricted patients' daily lives, careers, and mental health.

Vitiligo — Phase II/III Research

Vitiligo research represents afamelanotide's most advanced pipeline indication beyond EPP. A landmark 2013 randomized controlled trial published in _JAMA Dermatology_ (Grimes et al.) evaluated afamelanotide combined with narrowband UVB (NB-UVB) phototherapy versus NB-UVB alone in 55 patients with generalized vitiligo. Key findings included:

• Combination therapy produced significantly faster onset of repigmentation (median 46 days vs. 64 days for NB-UVB alone)
• Greater percentage of body surface area repigmented at all time points through 6 months
• Superior outcomes on the face and upper extremities, areas most visible and impactful for patient quality of life
• Repigmentation was more sustained in the combination group during follow-up

The mechanism appears synergistic: NB-UVB activates melanocyte stem cells in hair follicles and lesion margins, while afamelanotide stimulates their proliferation, migration into depigmented areas, and melanin production once positioned. Subsequent studies have confirmed these findings, and larger Phase III trials are anticipated to support a potential regulatory filing for this indication.

Polymorphous Light Eruption (PMLE)

PMLE is the most common photosensitivity disorder, affecting up to 20% of the population in temperate climates. A Phase II proof-of-concept study examined afamelanotide's ability to prevent PMLE lesions triggered by controlled UV exposure. Patients receiving afamelanotide showed significantly reduced PMLE symptoms following UV provocation, with measurable increases in minimal erythema dose (MED)—the amount of UV required to produce reddening. The increased melanin density appeared to reduce UV penetration to the depths where the immune-mediated PMLE response originates.

Organ Transplant Photoprotection

Solid organ transplant recipients on long-term immunosuppression face a 65-250× increased risk of squamous cell carcinoma and other UV-related skin cancers. A Phase II pilot study investigated whether afamelanotide-induced melanization could provide an additional layer of photoprotection for these high-risk patients. Results showed significant increases in melanin density and measurable reductions in UV-induced DNA damage biomarkers (sunburn cells, p53 expression) in afamelanotide-treated skin. While promising, larger and longer-term studies are needed to determine whether this translates to reduced skin cancer incidence.

Melanin Density and Photoprotection Quantification

Across all clinical studies, objective measurements using spectrophotometry and reflectance confocal microscopy consistently demonstrate that afamelanotide increases melanin density in both constitutively pigmented and UV-naïve skin. Increases in melanin density of 15-50% have been documented depending on baseline skin type, with the greatest relative increases in fair-skinned individuals (Fitzpatrick I-III). These melanin increases correlate with measurable improvements in UV protection, as demonstrated by increased minimal erythema dose (MED) values.

Dosage and administration

⚠️ Warning: The following information reflects approved clinical dosing and research protocols. Afamelanotide (Scenesse) is only available through a restricted program and must be administered by a healthcare professional. Self-administration of research-grade peptides carries significant risks including contamination, incorrect dosing, and absence of medical oversight.

Approved Clinical Dosing (Scenesse)

| Indication | Dose | Route | Frequency |

| --- | --- | --- | --- |

| EPP (FDA-approved) | 16 mg implant | Subcutaneous (supra-iliac) | Every 60 days |

| Vitiligo (investigational) | 16 mg implant + NB-UVB | Subcutaneous + phototherapy | Every 28 days (study-dependent) |

| PMLE (investigational) | 16 mg implant | Subcutaneous | Pre-seasonal, every 60 days |

Administration Procedure

The Scenesse implant is inserted subcutaneously by a trained healthcare provider using a custom catheter applicator. The standard insertion site is the supra-iliac crest region (above the hip bone), alternating sides with each administration. The area is cleaned and local anesthesia may be applied if needed. The implant—a small rod approximately 1.7 cm × 1.45 mm—is deposited into the subcutaneous fat layer through a small puncture. No sutures are required, and the implant fully dissolves within approximately 50-60 days.

Research Dosing Context

Early clinical studies explored injectable formulations at doses ranging from 0.08 mg/kg to 0.40 mg/kg administered intravenously or subcutaneously. However, the short plasma half-life of approximately 30 minutes following IV administration necessitated the development of the sustained-release implant to achieve clinical utility. Some studies have examined repeated lower-dose subcutaneous injections (0.5-1.0 mg daily) in research settings, though the implant formulation has become the standard for all clinical programs.

Timing and Seasonal Considerations

For EPP patients, dosing is recommended before and during periods of expected sunlight exposure—typically spring through autumn in temperate climates. Clinical trial protocols allow up to four implants per year in European labeling. Visible skin darkening typically begins within 5-10 days of implant insertion. For vitiligo studies, afamelanotide dosing is coordinated with NB-UVB phototherapy sessions for synergistic effect.

Monitoring Requirements

The Scenesse REMS program requires full-body skin examinations at baseline and every six months during treatment. Clinicians should document the number, location, and characteristics of melanocytic nevi before initiating therapy and monitor for any changes. Patients should report any new or changing moles between scheduled examinations. Implant site should be checked for signs of infection, extrusion, or local reaction at follow-up visits.

Safety and side effects

Afamelanotide benefits from the most comprehensive safety database of any melanocortin agonist, with clinical trial data spanning over 1,200 patient-years of exposure across multiple Phase II and Phase III studies, plus post-marketing surveillance data since EMA approval in 2014.

Common Side Effects

| Side Effect | Frequency | Notes |

| --- | --- | --- |

| Nausea | 17-22% | Usually mild, resolves within 24-48 hours post-implantation |

| Headache | 12-15% | Transient, typically self-limiting |

| Implant site reaction | 10-20% | Redness, pain, or discoloration; resolves as implant dissolves |

| Skin darkening | Expected effect | Generalized melanization—desired pharmacological effect |

| Nasopharyngitis | 8-12% | Upper respiratory symptoms; similar to placebo rate |

| Oropharyngeal pain | 5-8% | Mild throat discomfort |

Dermatological Monitoring Considerations

The most important safety consideration with afamelanotide relates to its effects on melanocytes. Clinical trials have documented:

• Darkening of existing nevi: Pre-existing moles may become darker during treatment. This is expected given the pharmacological mechanism but necessitates monitoring to distinguish drug-related darkening from dysplastic changes.
• New nevi formation: Some patients develop new melanocytic nevi during treatment. The rate appears comparable to age-matched controls, but systematic tracking is required.
• Ephilides (freckles): Increased freckling has been observed, particularly in fair-skinned individuals.

To date, no increased incidence of melanoma has been identified in afamelanotide-treated patients in clinical trials or post-marketing surveillance. Preclinical studies specifically evaluating tumorigenicity showed no melanoma-promoting effect. The MC1R pathway actually appears to have tumor-suppressive properties through enhanced DNA repair. However, long-term epidemiological data are still accumulating.

📝 Note: The theoretical concern about melanocortin stimulation and melanoma risk has been extensively studied. Current evidence suggests MC1R-selective agonists like afamelanotide may actually be protective by promoting eumelanin over pheomelanin and enhancing DNA repair, but continued pharmacovigilance is warranted.

Comparison with Melanotan II Safety

Afamelanotide's MC1R selectivity gives it a markedly different safety profile compared to the non-selective Melanotan II. Adverse effects commonly associated with Melanotan II—including spontaneous penile erections, appetite suppression, facial flushing, and blood pressure changes—are absent or rare with afamelanotide due to its minimal activity at MC3R, MC4R, and MC5R subtypes. This selectivity is a direct result of the linear peptide structure that favors MC1R over the other melanocortin receptors.

Contraindications and Special Populations

Afamelanotide has not been studied in pregnant or breastfeeding women and should not be used during pregnancy. Patients with hepatic or renal impairment should use caution, though no dose adjustments are specified in the current labeling. The drug has not been studied in pediatric populations. Patients with a personal or family history of melanoma should undergo careful benefit-risk assessment before initiating therapy.